Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Glioblastoma 2 Spondylitis, Ankylosing 1 Signs and Symptoms 1 Psoriasis 1 Nutrition Disorders 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Insulin Resistance 1 Inflammatory Bowel Diseases 1 Glioma 1 Gastroparesis 1 Feeding and Eating Disorders 1 Esophageal Neoplasms 1 Epilepsy 1 Dumping Syndrome 1 Diarrhea 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Cytarabine 561 Azacitidine 385 venetoclax 311 Cyclophosphamide 289 fludarabine 246 fludarabine phosphate 229 Decitabine 187 Busulfan 176 Daunorubicin 155 Idarubicin 151 Peripheral Blood Stem Cell Transplantation 138 Mycophenolic Acid 134 Filgrastim 134 Whole-Body Irradiation 133 Tacrolimus 125 Granulocyte Colony-Stimulating Factor 124 Etoposide 117 Mitoxantrone 103 Methotrexate 103 Melphalan 103 Cyclosporine 101 Antilymphocyte Serum 85 Gemtuzumab 84 Clofarabine 84 Specimen Handling 73 Injections 69 Stem Cell Transplantation 64 Biopsy 57 CPX-351 56 Thiotepa 54

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Leukemia, Myeloid, Acute × Sulfasalazine × Clear all

NCT05580861 2024-05-29

SALMA

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡